You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR DUPILUMAB


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for dupilumab

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01312961 ↗ Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma Completed Regeneron Pharmaceuticals Phase 2 2011-03-01 Primary Objective: To investigate the effects of Dupilumab (SAR231893/REGN668) administered subcutaneously (SC) once weekly (qw) for 12 weeks as compared to placebo on reducing the incidence of asthma exacerbation in participants with persistent moderate to severe eosinophilic asthma. Secondary Objectives: - To assess the safety and tolerability of Dupilumab administered SC qw for 12 weeks in participants with persistent moderate to severe eosinophilic asthma. - To assess Dupilumab serum concentrations following qw SC dosing for 12 weeks in participants with persistent moderate to severe eosinophilic asthma.
NCT01312961 ↗ Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma Completed Sanofi Phase 2 2011-03-01 Primary Objective: To investigate the effects of Dupilumab (SAR231893/REGN668) administered subcutaneously (SC) once weekly (qw) for 12 weeks as compared to placebo on reducing the incidence of asthma exacerbation in participants with persistent moderate to severe eosinophilic asthma. Secondary Objectives: - To assess the safety and tolerability of Dupilumab administered SC qw for 12 weeks in participants with persistent moderate to severe eosinophilic asthma. - To assess Dupilumab serum concentrations following qw SC dosing for 12 weeks in participants with persistent moderate to severe eosinophilic asthma.
NCT01385657 ↗ Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis Completed Sanofi Phase 1 2011-07-31 The purpose of this study is to assess the safety and tolerability of repeated subcutaneous (SC) doses of Dupilumab in participants with moderate-to-severe atopic dermatitis (AD).
NCT01385657 ↗ Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis Completed Regeneron Pharmaceuticals Phase 1 2011-07-31 The purpose of this study is to assess the safety and tolerability of repeated subcutaneous (SC) doses of Dupilumab in participants with moderate-to-severe atopic dermatitis (AD).
NCT01548404 ↗ Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis Completed Sanofi Phase 2 2012-04-01 The primary objective was to assess the clinical efficacy of repeated subcutaneous (SC) doses of Dupilumab in adult participants with moderate-to-severe atopic dermatitis (AD).
NCT01548404 ↗ Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis Completed Regeneron Pharmaceuticals Phase 2 2012-04-01 The primary objective was to assess the clinical efficacy of repeated subcutaneous (SC) doses of Dupilumab in adult participants with moderate-to-severe atopic dermatitis (AD).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for dupilumab

Condition Name

Condition Name for dupilumab
Intervention Trials
Atopic Dermatitis 41
Asthma 22
Dermatitis, Atopic 8
Chronic Rhinosinusitis With Nasal Polyps 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for dupilumab
Intervention Trials
Dermatitis 60
Dermatitis, Atopic 56
Eczema 54
Asthma 25
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for dupilumab

Trials by Country

Trials by Country for dupilumab
Location Trials
United States 956
Canada 120
Japan 114
Germany 86
Poland 85
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for dupilumab
Location Trials
California 60
Florida 46
New York 45
Texas 44
Pennsylvania 39
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for dupilumab

Clinical Trial Phase

Clinical Trial Phase for dupilumab
Clinical Trial Phase Trials
Phase 4 42
Phase 3 43
Phase 2/Phase 3 5
[disabled in preview] 51
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for dupilumab
Clinical Trial Phase Trials
Recruiting 56
Completed 41
Not yet recruiting 32
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for dupilumab

Sponsor Name

Sponsor Name for dupilumab
Sponsor Trials
Regeneron Pharmaceuticals 95
Sanofi 80
National Institute of Allergy and Infectious Diseases (NIAID) 8
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for dupilumab
Sponsor Trials
Industry 192
Other 79
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.